NEW YORK (GenomeWeb News) – Beckman Coulter this week set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55. According to Thomas Weisel Partners analyst Peter Lawson, the guidance is below analysts' consensus estimate of $4.56.
"While initial 2010 guidance was below consensus, we believe management is maintaining a conservative outlook on the Olympus synergies and economic conditions," he wrote in a research note published Thursday evening.
Beckman acquired Olympus' diagnostics business earlier this year for $780 million in a deal expected to expand Beckman's clinical chemistry offering with particular strength in the larger hospital laboratories.
UK molecular diagnostics testing services firm Lab21 will open its US headquarters in Greenville County, South Carolina, according to a statement issued this week by that state's Department of Commerce. The CLIA lab, with a particular focus on oncology testing, is expected to open early next year.
Pacific Biometrics this week announced that its shareholders have approved a change in the company's name to Pacific Biomarkers. It also said that shareholders had re-elected all seven members of its board of directors: Ronald Helm; Mario Ehlers; Paul Kana; Richard Palfreyman; Curtis Scheel; Stanley Schloz; and Kenneth Waters.
Caprion Proteomics has purchased back a subordinated promissory note from Thallion Pharmaceuticals for an immediate cash payment of $1,850,000. The promissory note was initially issued by Caprion in July 2007 as part of the proceeds from the sale of Thallion's proteomics business. Thallion said that it continues to retain its roughly 16 percent equity stake in Caprion.
The Federation of American Societies for Experimental Biology this week announced that the Genetics Society of America and the American Federation for Medical Research are the newest members of FASEB.